There were 134 press releases posted in the last 24 hours and 195,280 in the last 365 days.

Meningococcal Vaccine Market To Reach $4,192.6 million by 2026 | Pfizer, Sanofi, Walvax Biotechnology

Meningococcal Vaccine Market

Meningococcal Vaccine Market

global meningococcal vaccine market is projected to reach $4,192.6 million by 2026, registering a CAGR of 9.5% from 2019 to 2026.

PORTLAND, OREGON, UNITED STATES, October 23, 2020 / -- global meningococcal vaccines market garnered $1.93 million in 2018, and is expected to generate $4.19 billion by 2026, registering a CAGR of 9.5% from 2019 to 2026. The report offers an extensive analysis of changing market dynamics, top impacting factors, business performance, major segments, and competitive heat map.

Request Sample Report at:

Covid-19 scenario

Due to lockdown, immunization programs will come to a halt and program schedules will be changed in various countries.
Research and development activities for vaccine technology will be limited, as researchers need to stay at home during the lockdown.
Meningococcal vaccine is used as a placebo effect in the Covid-19 vaccine trial conducted at the University of Oxford.

Do Purchase Enquiry at:

Frontrunners in the industry-

Bio-Med Pvt. Limited
Chongqing Zhifei Biological Products Co., Ltd.
GlaxoSmithKline Plc
Hualan Biological Engineering Inc.
Incepta Pharmaceuticals Ltd.
Pfizer Inc.
Sanofi S.A.
Serum Institute of India Pvt. Ltd.
Walvax Biotechnology Co., Ltd.

Access Full Report Summary:

North America to maintain its dominance throughout the forecast period

Based on region, North America accounted for the largest market share in terms of revenue in 2018, holding nearly half of the global meningococcal vaccine market, and is estimated to maintain its lead position throughout the forecast period. This is due to surge in prevalence of meningitis disease and ease in availability of meningococcal vaccine products for treatment of the disease. However, Asia-Pacific is expected to portray the largest CAGR of 14.7% from 2019 to 2026, owing to surge in outbreaks of meningococcal diseases and widespread availability of products.

Similar Reports:

Zika Virus Vaccines Market is estimated to reach $18,697 million by 2022

Cancer Pain Market is projected to reach $7,545 million by 2025

Anti-Rheumatics Market is expected to reach $71,934 million by 2026

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

David Correa
Allied Analytics LLP
+1 800-792-5285
email us here
Visit us on social media: